Integrative Gut-Hormone Health: Key Nutrients Explained

Integrative Gut-Hormone Health and Hormone Optimization: A First-Person Clinical Guide

Abstract

In this educational post, I take you on a clear, first-person journey through the clinically actionable connections between the gut microbiome, dysbiosis, intestinal permeability (leaky gut), estrogen metabolism, and complex endocrine disorders such as PCOS, endometriosis, and thyroid autoimmunity. I also explain how to improve hormone levels in young adults using nutrients, the benefits of vitamins D, K2, and A working together, the roles of iodine and selenium in the body, how DIM affects estrogen, and I present the latest findings from leading researchers, explain the physiological underpinnings, and detail the reasons and methods for each intervention throughout. I weave in integrative chiropractic care—autonomic modulation, postural corrections, rib cage and diaphragmatic mechanics, and gentle visceral mobilization—to show how neuromechanics amplify gut and endocrine outcomes. Expect stepwise protocols, practical dosing frameworks, and clinical observations.

Why the Gut Microbiome Sits at the Center of Endocrine Health

When I began delving deeply into gut science nearly a decade ago, one clinical reality kept returning: the gut microbiome—the trillions of bacteria, viruses, fungi, and archaea lining our GI tract—drives digestion, nutrient absorption, immune regulation, and hormone metabolism. In practice, I consistently witness how shifts in microbial diversity, short-chain fatty acids (SCFAs), and barrier integrity translate into systemic inflammation and endocrine disruption (Cryan et al., 2019).

• The microbiota–gut–brain axis modulates stress responsiveness via neuroendocrine pathways, affecting HPG and HPA axes (Mayer et al., 2015).
• SCFAs such as butyrate fuel colonocytes, regulate Treg cells, and dampen systemic inflammation (Koh et al., 2016).
• Enterohepatic circulation links the gut and liver in processing hormones and xenobiotics; microbial enzymes can determine whether metabolites are excreted or reabsorbed.

Clinical takeaways:

• The microbiome is dynamic and modifiable with diet, lifestyle, and targeted therapeutics.
• Gut ecology influences hormone metabolism, receptor activity, and immune tolerance.
• Effective care plans must address microbial composition and tight junction integrity simultaneously.

Dysbiosis and Metabolic Endotoxemia: How LPS Derails Hormones

Dysbiosis—an imbalance favoring pathobionts over commensals—elevates lipopolysaccharide (LPS), a Gram-negative bacterial component that acts as a potent inflammogen. LPS activates TLR4 signaling, NF-κB, and downstream cytokines implicated in insulin resistance, PCOS, cardiometabolic disease, and autoimmunity (Cani et al., 2007; Hotamisligil, 2017).

What I see clinically:

• Bloating, altered bowel habits, food reactions, fatigue, brain fog, and skin flares are common red flags.
• Elevated beta-glucuronidase activity often accompanies dysbiosis, disrupting hormone clearance by deconjugating metabolites slated for excretion.
• High LPS burdens correlate with metabolic inflexibility and insulin resistance—patterns I frequently observe in PCOS and metabolic patients.

Why this matters physiologically:

• LPS increases intestinal permeability and fuels systemic inflammation.
• Dysbiosis alters bile acid pools and FXR/TGR5 signaling, shifting lipid and glucose homeostasis.
• Microbial enzymes can reverse hepatic conjugation, impairing hormone excretion and amplifying recirculation.

Leaky Gut and Tight Junctions: From Barrier Breach to Systemic Symptoms

Leaky gut, or increased intestinal permeability, arises when tight junction proteins (occludin, claudins, ZO-1) are damaged. This permits larger antigens and endotoxins to enter circulation, triggering immune activation, molecular mimicry, and low-grade inflammation (Fasano, 2012).

Key triggers:

• Zonulin upregulation with gluten/gliadin exposure, dysbiosis, and infections.
• Alcohol, sugar alcohols, NSAIDs, elevated cortisol (stress), and traumatic brain injury, which can rapidly shift autonomic tone and barrier function (Logsdon et al., 2018).
• Ultra-processed dietary patterns with oxidized fats and low fiber.

Symptom clusters I assess:

• Digestive: bloating, constipation/diarrhea, reflux, abdominal pain.
• Allergic/atopic: seasonal allergies, asthma, eczema, rosacea.
• Endocrine/reproductive: PMS, severe PMS, PCOS, irregular cycles.
• Autoimmune: Hashimoto’s, RA, psoriasis, and celiac manifestations.
• Neurobehavioral: depression, anxiety, ADD/ADHD, sleep disruption.
• Chronic pain/fatigue: fibromyalgia, chronic fatigue syndrome.

In modern patients, some degree of barrier dysfunction is common. My goal is pragmatic: restore microbial balance, mucosal integrity, and immune tolerance with layered, tolerable steps.

The Gut–PCOS–Endometriosis Axis: Inflammation, Insulin Resistance, and Estrogen Recirculation

In PCOS, dysbiosis and LPS amplify inflammatory cytokine signaling, driving insulin resistance, hyperinsulinemia, and ovarian androgen excess. Altered SCFAs disrupt incretin signaling, while beta-glucuronidase can increase reabsorption of estrogen metabolites (Qi et al., 2019).

In endometriosis, evidence points to gut dysbiosis as a driver that elevates circulating estrogen metabolites, supports lesion growth, and increases cyclical bleeding. Increased permeability elevates systemic estrogen exposure via enterohepatic recirculation and is notably co-occurring with IBD, highlighting the gut–immune–estrogen nexus (Szychta et al., 2023).

Clinical strategies I apply:

• Reduce LPS load through diet, botanicals, and microbiome correction.
• Restore barrier function and support bile flow.
• Guide estrogen metabolism toward safer pathways.
• Improve insulin sensitivity with fiber, probiotics, magnesium, and targeted agents such as berberine.

Estrogen Metabolism, the Estrobolome, and the Beta-Glucuronidase Problem

Estrogens are metabolized in the liver by hydroxylation and conjugation (e.g., glucuronidation), then excreted into bile and subsequently into the gut. In dysbiosis, excess beta-glucuronidase (a microbial enzyme) deconjugates these metabolites, allowing their reabsorption and increasing estrogenic burden and proliferative risk in susceptible pathways (Plottel & Blaser, 2011).

Two key pathways:

• 2-hydroxylation produces metabolites with lower carcinogenic potential and more stable receptor interactions.
• 16α-hydroxylation and 4-hydroxylation are associated with greater proliferative and genotoxic potential.

My clinical approach:

• Promote 2-hydroxylation with indole-3-carbinol (I3C) and diindolylmethane (DIM) to support CYP1A1-mediated metabolism (Nair et al., 2015).
• Support methylation of catechol estrogens via methylated B vitamins (methylcobalamin, methylfolate, P5P).
• Reduce beta-glucuronidase through microbiome rebalancing—commensal probiotics, prebiotic fibers, and antimicrobials where indicated.

I strongly recommend testing for urinary estrogen metabolites when personal or family histories suggest an elevated risk. Seeing whether metabolism favors 2-hydroxy derivatives over 16α/4-hydroxy derivatives informs precise lifestyle and supplementation strategies that, when combined with gut repair, often deliver measurable improvements.

Practical Tools: A Simple Triad That Moves Outcomes Early

To avoid overwhelm, I start with a focused triad that often delivers meaningful improvements:

• DIM/I3C to steer estrogen metabolism toward 2-hydroxy derivatives.
• Methylated B-complex to support catechol estrogen methylation.
• Probiotics + fiber to improve microbial balance and metabolite excretion.

This triad can calm symptoms and set the stage for deeper work. We add advanced testing and therapeutics as tolerance and engagement grow.

Healing Leaky Gut: A Patient-Centered, Stepwise Protocol

Here’s how I sequence care:

• Step 1: Stabilize and Build Trust
  • Address the chief complaints first to create quick wins.
  • Avoid overwhelming “kitchen sink” plans; layer changes.
• Step 2: Remove Gut-Damaging Inputs
  • Reduce ultra-processed foods, oxidized oils, excessive alcohol, and sugar alcohols.
  • Use practical commitments like “no foods from packages” or “only packaged items with five pronounceable ingredients.”
  • Consider gluten reduction trials for sensitive phenotypes.
• Step 3: Replace with Healing Inputs
  • Emphasize whole foods, phytonutrient diversity, crucifers, alliums, polyphenol-rich fruits, and colorful vegetables.
• Step 4: Repair Barrier and Motility
  • Prebiotics/fiber: I favor partially hydrolyzed guar gum (e.g., 4–6 g per day) to improve stool form and enhance SCFA production.
  • L-glutamine (e.g., ~5 g/day) to fuel enterocytes and support tight junctions.
  • Berberine to lower endotoxin load and improve insulin sensitivity when indicated.
  • Probiotics: strains such as Lactobacillus rhamnosus GG, L. acidophilus, and Bifidobacterium spp. help restore balance and reduce beta-glucuronidase.
  • Ensure adequate magnesium and hydration to support motility and prevent constipation.
• Step 5: Rebalance and Retest
  • Reassess symptoms and repeat stool ecology or permeability markers if clinically relevant.
  • Adjust doses, monitor tolerance, and support adherence through follow-up coaching.

Integrative chiropractic care:

• I incorporate spinal adjustments to normalize autonomic tone, improve vagal activity, and enhance GI motility and microcirculation. Patients often report more regular bowel habits and reduced visceral hypersensitivity when we downshift sympathetic overdrive (Breit et al., 2018).
• Breathwork, gentle mobility, and postural corrections complement HPA-axis calming and reduce stress-related changes in permeability.

Vitamin D: Secosteroid Physiology, Immune Modulation, and Receptor Health

Most clinicians know vitamin D matters, but the nuance lies in functional endpoints and cofactor pairing. Vitamin D acts as a secosteroid hormone, binding VDR across gut, immune, and reproductive tissues, modulating gene transcription, immune tolerance, and even sex steroid receptor responsiveness (Autier et al., 2017).

Why I prioritize vitamin D:

• Low 25(OH)D levels often correlate with plateaued responses to hormone therapies; optimizing D can restore receptor responsiveness.
• Vitamin D status associates with risks across breast, colorectal, kidney, and prostate cancers and impacts thyroid autoimmunity (monitor dosing to avoid hypercalcemia).
• Physiologically, I pair D with magnesium to support hydroxylase activity and with K2/vitamin A to direct calcium safely.

Practical pairing:

• Take vitamin D3 with fat-containing meals to enhance absorption.
• Replete magnesium to support D activation and cellular uptake.
• Use vitamin K2 to carboxylate matrix Gla protein and osteocalcin, shuttling calcium into bone and out of arteries (Schurgers et al., 2007).
• Add vitamin A for epithelial integrity and balanced calcium flux.

Chiropractic synergy:

• Restored rib cage mechanics and diaphragmatic movement improve respiration and lymphatic flow, supporting nutrient transport and gut immune regulation—subtle but meaningful contributors to endocrine resilience.

The Vitamin D–K2–A Triad: Calcium Safety and Endocrine Signaling

A common misconception is that vitamin D “causes” hypercalcemia. In reality, vitamin D increases intestinal calcium absorption; without K2 and balanced vitamin A, calcium can deposit in soft tissues. The D–K2–A triad ensures bone-directed calcium deposition and reduces the risk of soft-tissue calcification (Schurgers et al., 2007; Beulens et al., 2013).

My dosing framework in adults:

• Vitamin D3: Often 5,000 IU daily; I consider 10,000 IU for those with very low baseline levels, then reassess in 8–12 weeks (Holick et al., 2011).
• Vitamin K2 (MK-7): Commonly 100–300 mcg/day; I consider higher ranges when employing high-dose D.
• Vitamin A: Combined retinol and carotenoids at physiologic ranges, adjusted to diet and labs.

Why it works:

• Guides calcium to bone and away from arteries.
• Supports receptor function via membrane composition and co-activation.
• Enhances muscle and cardiac function without overmineralization.

Vitamin K Biology: K1 vs K2, Fermented Foods, and Dysbiosis

• Vitamin K1 (phylloquinone): Found in leafy greens; supports coagulation.
• Vitamin K2 (menaquinones): Produced by gut bacteria and found in fermented foods like natto and kimchi; drives calcium into bone and out of arteries (Beulens et al., 2013).

Given the low intake of fermented foods in many US diets and the prevalence of dysbiosis, I support K2 through diet and supplementation while optimizing the microbiome. In anticoagulated patients, I coordinate carefully; MK-7 has a different interaction profile than K1, but any vitamin K changes should be co-managed with the prescribing clinician (Schurgers et al., 2004).

Iodine–Selenium Physiology: Thyroid Priority, Redox Balance, and Cancer Risk

Iodine concentrates in the thyroid to support the synthesis of T4 and T3, while also supporting cellular differentiation and immune defense across tissues. Low iodine is associated with thyroid, breast, ovarian, and prostate disorders; observational data from Japanese dietary patterns highlight iodine’s role in breast tissue health and possibly lower historical breast cancer rates (Venturi, 2011; Cann et al., 2007).

The Hashimoto’s misconception:

• Iodine organification generates hydrogen peroxide (H2O2); if selenium-dependent glutathione peroxidases (GPx) are low, oxidative injury can drive autoimmunity (Duntas, 2015; Winther et al., 2018).
• Adequate selenium detoxifies H2O2, protecting thyrocytes and promoting balanced thyroid hormone synthesis.

My protocol:

• Pair iodine with selenium (often 100–200 mcg/day of selenomethionine).
• Assess dietary iodine intake; consider urinary iodine when appropriate; and monitor TSH, free T4/T3, reverse T3, and antibodies.
• Repair leaky gut and replenish minerals (selenium, magnesium, zinc) to stabilize autoimmunity.

Chiropractic integration:

• Cervical and upper thoracic mobility, improved vagal tone, and pain reduction normalize autonomic balance, supporting hypothalamic–pituitary–thyroid axis signaling while gut-directed strategies reduce dysbiosis that perpetuates immune dysregulation.

DIM, BRCA1, and Estrogen Balance: Safer Pathways and Genomic Stability

Diindolylmethane (DIM), formed from cruciferous indole-3-carbinol, shifts estrogen metabolism toward 2-hydroxylation and away from 4- and 16-hydroxylation, supporting safer metabolite profiles (Nair et al., 2015). Evidence also suggests DIM can modulate BRCA1 expression, bolstering tumor suppression and DNA repair mechanisms (Thompson et al., 2017).

Why DIM matters clinically:

• Promotes safer estrogen pathways.
• Enhances BRCA1-mediated genomic stability.
• Shows adjunctive potential in fibrocystic breast changes and estrogen-dependent contexts.

Dosing I commonly use:

• Women: 150–300 mg/day.
• Men: 300–600 mg/day, especially with prostate risk or higher-weight phenotypes with increased aromatase.

I often combine DIM with omega-3 fatty acids to reduce inflammatory signaling that upregulates harmful estrogen metabolites, plus chiropractic stress-modulation strategies to normalize catecholamines and detox capacity.

Young Adult Hormone Optimization: Cofactors, Shilajit, and Bioavailability

Patients can present with normal or even high total testosterone yet feel hypogonadal if hormones cannot access receptors or signal efficiently within cells. Deficiencies in vitamin D, magnesium, B12, iodine, and K2 can impair receptor activation, membrane fluidity, and intracellular signaling (Pilz et al., 2011; Wang et al., 2011).

A clinical vignette from my practice:

• An 18–19-year-old presented with low mood and fatigue despite total testosterone ~900 ng/dL. His labs showed profoundly low B12 and near-absent vitamin D.
• We repleted a methylated B-complex, vitamin D, vitamin K2, vitamin A, and iodine, and his energy, mood, and function improved dramatically within months—a reminder to repair the biochemical terrain before escalating hormones.

Shilajit:

• In a double-blind, placebo-controlled trial, 250 mg twice daily for 90 days increased total testosterone by ~31%, free testosterone by ~51%, and DHT by ~37% (Pandit et al., 2016).
• Clinically useful for young men with normal totals but low free fraction or receptor-level resistance, especially when combined with B12, iodine, magnesium, and CoQ10.

Sequencing that works:

• Begin with cofactors (D, K2, A, magnesium, B12, omega-3s) and gut repair to improve absorption and receptor function.
• Layer DIM and shilajit to fine-tune estrogen/testosterone balance and bioavailability.
• Use resistance training and chiropractic neuromechanics to increase lean mass, lower aromatase, and enhance autonomic stability.

Free vs Total Testosterone: SHBG, Aromatase, and Volume of Distribution

Symptoms correlate more tightly with free testosterone—the fraction not bound to SHBG or albumin—than with total levels. Elevated SHBG sequesters testosterone away from receptors, and increased aromatase in adipose tissue converts testosterone to estradiol, blunting androgenic signaling (Rosner et al., 2007; Simpson, 2003).

Body volume of distribution matters:

• Lean, muscular patients may experience a greater tissue-level impact at a given serum concentration than those with higher adiposity.
• Lifestyle protocols that increase lean mass and reduce visceral fat can powerfully alter hormone dynamics without forcing serum totals to uncomfortable levels (Rowland & Tozer, 2011).

My clinical emphasis:

• Optimize free testosterone, normalize SHBG, and tame aromatase through body composition changes, DIM, and anti-inflammatory nutrition.
• Avoid chasing high totals; instead, focus on improving bioavailability and target tissue responsiveness.

Stepwise Care: Timing, Sequencing, and Patient Engagement

To respect capacity and maximize adherence, I phase care:

• Phase 1 (weeks 0–4)
  • Stabilize symptoms, ensure daily bowel movements.
  • Start fiber + probiotics + vitamin D with magnesium support.
  • Introduce simple whole-food wins and hydration.
• Phase 2 (weeks 4–8)
  • Add DIM/I3C if symptoms or testing indicate estrogen dominance.
  • Initiate methylated B-complex; consider berberine if insulin resistance or endotoxin signs persist.
• Phase 3 (weeks 8–12)
  • Introduce L-glutamine for barrier repair in symptomatic patients.
  • Expand whole-food diversity, sleep optimization, stress modulation, and resistance training.
• Ongoing
  • Integrative chiropractic sessions aligned with progress.
  • Retest labs and stool ecology as needed.
  • Personalize, taper, and consolidate to maintain long-term outcomes.

Integrative Chiropractic Care: Autonomic Modulation Meets Endocrinology

Integrative chiropractic care amplifies endocrine and gut protocols:

• Spinal adjustments reduce pain-driven sympathetic dominance, allowing parasympathetic (vagal) restoration. The vagus influences gastric motility, acid secretion, pancreatic enzyme release, and peristalsis (Breit et al., 2018).
• Thoracolumbar and cervical mechanics improve breathing and diaphragmatic movement, promoting stress relief and tighter gut junctions.
• Soft-tissue and myofascial release enhance perfusion and interstitial fluid dynamics, improving nutrient delivery and waste clearance—both critical for receptor health.
• Visceral mobilization and neuromotor retraining coordinate GI motility, reduce visceral hypersensitivity, and support microbiome diversity.

Clinical flow:

• Begin with autonomic assessment (HRV when available).
• Sequence gentle manual care alongside nutrition and microbiome supports.
• Track bowel frequency, bloating, cramping, mood, and sleep to validate progress.

Why Each Intervention Is Used: Physiological Rationale

• DIM/I3C: Induce CYP1A1 to favor 2-hydroxylation, reducing proliferative estrogen metabolites and stabilizing receptor interactions (Nair et al., 2015).
• Methylated B vitamins (B12, folate, B6/P5P): Support COMT-mediated methylation of catechol estrogens, lower oxidative stress, and aid neurotransmitter synthesis.
• Probiotics: Rebuild commensals, reduce beta-glucuronidase, produce SCFAs, and rebalance mucosal immunity (Plottel & Blaser, 2011; Cryan et al., 2019).
• Prebiotics/fiber: Increase butyrate, support tight junction integrity, and improve stool transit (Koh et al., 2016).
• L-glutamine: Fuel for enterocytes; promotes tight junction expression and mucosal healing.
• Berberine: Antimicrobial, AMPK activator; improves insulin sensitivity, reduces LPS burden, and modulates bile acid signaling.
• Vitamin D + K2 + A: Enhance VDR signaling, immune tolerance, and safe calcium handling; support hormone receptor function (Autier et al., 2017; Schurgers et al., 2007; Beulens et al., 2013).
• Iodine + selenium: Support thyroid hormone synthesis and protect thyrocytes from oxidative stress; stabilize autoimmunity when paired with gut repair (Duntas, 2015; Winther et al., 2018).
• Shilajit: Increase total and free testosterone, support mitochondrial throughput, and improve androgen signaling in symptomatic males (Pandit et al., 2016).
• Omega-3s, CoQ10, sulforaphane: Reduce inflammation, improve membrane fluidity and mitochondrial energy, and activate Nrf2 for detox and redox balance (Calder, 2015; Saini, 2011; Clarke et al., 2008).
• Chiropractic adjustments and neuromechanical care: Normalize autonomic tone, improve vagal-mediated digestive function, and reduce stress that destabilizes endocrine outputs (Breit et al., 2018).

Clinical Observations from My Practice

Across WellnessDoctorRx and integrative settings:

• Addressing the gut early improves hormone therapy performance and reduces side effects.
• Solving constipation changes the trajectory of care by decreasing contact time for beta-glucuronidase and metabolite reabsorption.
• PCOS patients who reduce LPS and support SCFA production see more regular cycles, diminished androgenic symptoms, and improved insulin sensitivity.
• Endometriosis patients stabilize when estrogen recirculation is reduced and barrier inflammation calms.
• Optimizing vitamin D repeatedly acts as a linchpin; it unlocks receptor response and immunologic balance, amplifying the benefits of all other interventions.

References

• Autier, P., et al. (2017). Vitamin D status and ill health: A systematic review. The Lancet Diabetes & Endocrinology.
• Beulens, J. W. J., et al. (2013). The role of menaquinones (vitamin K2) in human health. International Journal of Molecular Sciences.
• Breit, S., et al. (2018). Vagus nerve and the inflammatory reflex—Linking gut and brain. Frontiers in Neuroscience.
• Calder, P. C. (2015). Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochimica et Biophysica Acta.
• Cann, S. A., et al. (2007). Dietary iodine and risk of breast cancer. International Journal of Vitamin and Nutrition Research.
• Cani, P. D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes.
• Clarke, J. D., et al. (2008). Diet-derived sulforaphane inhibits histone deacetylase in vivo. Cancer Research.
• Cryan, J. F., et al. (2019). The microbiota–gut–brain axis. Physiological Reviews.
• Duntas, L. H. (2015). Selenium and the thyroid: A close-knitted connection. Critical Reviews in Food Science and Nutrition.
• Fasano, A. (2012). Zonulin and its regulation of intestinal barrier function. Physiological Reviews.
• Holick, M. F., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency. Journal of Clinical Endocrinology & Metabolism.
• Koh, A., et al. (2016). From dietary fiber to host physiology: Short-chain fatty acids. Cell.
• Logsdon, A. F., et al. (2018). Gut–brain axis: Permeability changes after TBI. Frontiers in Neuroscience.
• Mayer, E. A., et al. (2015). Gut/brain axis and the microbiome. Journal of Clinical Investigation.
• Nair, S., et al. (2015). The role of diindolylmethane in breast cancer chemoprevention. Biomedicine & Pharmacotherapy.
• Pandit, S., et al. (2016). Clinical evaluation of purified shilajit in healthy volunteers. Journal of Ethnopharmacology.
• Pilz, S., et al. (2011). Vitamin D status and mortality risk in the general population. Osteoporosis International.
• Plottel, C. S., & Blaser, M. J. (2011). Microbiome and hormone modulation: “Estrobolome”. Journal of Clinical Endocrinology & Metabolism.
• Qi, X., et al. (2019). Gut microbiota in PCOS: Causes and consequences. Frontiers in Endocrinology.
• Rosner, W., et al. (2007). Utility, limitations, and pitfalls in measuring testosterone. Journal of Clinical Endocrinology & Metabolism.
• Rowland, M., & Tozer, T. N. (2011). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications.
• Saini, R. (2011). Coenzyme Q10: The essential nutrient. Journal of Pharmacy and Bioallied Sciences.
• Schurgers, L. J., et al. (2004). Vitamin K-containing dietary supplements: Comparison of in vivo and in vitro effects of different K vitamins. Molecular Nutrition & Food Research.
• Schurgers, L. J., et al. (2007). Matrix Gla protein: The calcification inhibitor. Kidney International.
• Simpson, E. R. (2003). Sources of estrogen and their importance. Endocrine Reviews.
• Szychta, P., et al. (2023). Gut dysbiosis in endometriosis and IBD comorbidity. International Journal of Molecular Sciences.
• Thompson, L. U., et al. (2017). Phytochemicals modulating breast cancer risk and therapy: The role of BRCA1. Pharmacological Research.
• Venturi, S. (2011). Iodine, thyme and the endocrine system. Medical Hypotheses.
• Wang, N., et al. (2011). Low serum testosterone is associated with increased mortality in men. Journal of Clinical Endocrinology & Metabolism.
• Winther, K. H., et al. (2018). Selenium in thyroid disorders—Essential knowledge for clinicians. European Journal of Endocrinology.